Journal of Modern Oncology

Современная онкология

1815-14341815-1442

LLC Obyedinennaya Redaktsiya

26631

Articles

Статьи

Research Article

Minimal'naya ostatochnaya bolezn' pri V-kletochnom khronicheskom limfoleykoze

Минимальная остаточная болезнь при В-клеточном хроническом лимфолейкозе

Nikitin

E A

Никитин

Е А

Gretsov

E M

Грецов

Е М

Гематологический научный центр РАМН, Москва

15032006

VOL 8, NO1 (2006)

ТОМ 8, №1 (2006)

606609042020

2006

Consilium Medicum

ООО "Консилиум Медикум"

https://creativecommons.org/licenses/by-nc/4.0

https://modernonco.orscience.ru/1815-1434/article/view/26631

Появление новых вариантов лечения B-клеточного хронического лимфолейкоза (В-ХЛЛ) за последние 10 лет привело к тому, что у значительной части больных удается достичь полной и даже молекулярной или иммунофенотипической ремиссии. Принципиально важно, что сам по себе факт эрадикации минимальной остаточной болезни (МОБ) при В-ХЛЛ перестал обсуждаться исключительно в контексте аутологичной или аллогенной трансплантации костного мозга. Сегодня все больше данных о том, что молекулярная и иммунофенотипическая ремиссия при В-ХЛЛ может быть достигнута с помощью комбинированной химиотерапии и моноклональных антител. Предварительные данные нескольких исследований свидетельствуют, что от наличия или отсутствия МОБ на определенном этапе лечения может зависеть дальнейшая терапевтическая тактика. Иными словами, необходимость в исследовании МОБ постепенно выходит за рамки клинических испытаний и в ближайшие годы может стать частью рутинной клинической практики. В данном обзоре мы разбираем принципы оценки МОБ при В-ХЛЛ, а также проводим анализ опубликованных в последние годы исследований, в которых такая оценка проводилась.

B-клеточный хронический лимфолейкозремиссияминимальная остаточная болезньтрансплантацияантителаэрадикациякостный мозгалемтузумаб

Vuillier F, Claisse J.F, Vandenvelde C et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone - marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk. Lymphoma 1992; 7 (3): 195-204.

Bottcher S, Ritgen M, Pott C et al. Comparative analysis of minimal residual disease detection using four - color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004 Oct; 18 (10): 1637-45.

Provan D, Bartlett-Pandite L, Zwicky C et al. Eradication of polymerase chain reaction - detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996 Sep 15; 88 (6): 2228-35.

Bruggemann M, Droese J, Bolz I et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real - time quantitative PCR. Leukemia 2000 Aug; 14 (8): 1419-25.

Kneba M. Evaluating of MRD in CLL. Vth international workshop of the german CLL study group. 2004.

Clavio M, Miglino M, Spriano M et al. First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. Eur J Haematol 1998; 61 (3): 197-203.

Vuillier F, Scott-Algara D, Dighiero G. Extensive analysis of lymphocyte subsets in normal subjects by three - color immunofluorescence. Nouv Rev Fr Hematol 1991; 33 (1): 31-8.

Fischer M, Klein U, Kuppers R. Molecular single - cell analysis reveals that CD5-positive peripheral blood B cells in healthy humans are characterized by rearranged Vkappa genes lacking somatic mutation. J Clin Invest. 1997 Oct 1; 100 (7): 1667-76.

10.

Robertson L.E, Huh Y.O, Butler J.J et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992; 80 (1): 29-36.

11.

Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath- 1H) as first - line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100 (3): 768-73.

12.

Rawstron A.C, Kennedy B, Evans P.A et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98 (1): 29-35.

13.

Bosch F, Ferrer A, Lopez-Guillermo A et al: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976-84.

14.

Robak T, Blonski J.Z, Kasznicki M et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002; 3 (5): 244-50.

15.

Cazin B, Maloum K, Creteil M.D et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: final response and follow up in 75 patients. Blood 2003; 102: 438a.

16.

Gilleece M.H, Dexter T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993 Aug 1; 82 (3): 807-12.

17.

Rawstron A.C, Kennedy B, Moreton P et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004 Mar 15; 103 (6): 2027-31.

18.

Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-9.

19.

Montillo M, Cafro A.M, Tedeschi A et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87: 695-700.

20.

Montillo M, Tedeschi A, Rossi V et al. Sequential treatment with fludarabine and subcutaneous alemtuzumab is able to purge residual disease in patients with chronic lymphocytic leukemia. Haematol J 2004; 5 (Suppl. 2): S204.

21.

O’Brien S.M, Kantarjian H.M, Thomas D.A et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657-63.

22.

Wendtner C.M, Ritgen M, Schweighofer C.D et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093-101.

23.

Morra E, Nosari A, Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther 1999 Aug; 41 (4): 145-51.

24.

Kennedy B, Rawstron A, Carter C et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245-7.

25.

Osterborg A, Dyer M.J, Bunjes D et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567-74.

26.

Rai K.R, Freter C.E, Mercier R.J et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-7.

27.

Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005: E